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 ABSTRACT 
Amphetamine Sensitization and in vivo Microdialysis of the Nucleus Accumbens Core of Adult 
Male and Female Rats D2-Primed as Neonates 
by 
Zackary A. Cope 
Neonatal administration of quinpirole produces significant increases in D2 receptor sensitivity 
that persists into adulthood.  This phenomenon, known as D2 receptor priming, is consistent with 
pathology in schizophrenia. Rats were administered quinpirole or saline postnatally and raised to 
adulthood. In adulthood, rats were administered d-amphetamine sulfate or saline every other day 
and were placed in a locomotor arena where activity was measured over 7 trials. Results showed 
that D2-primed rats receiving amphetamine were higher in locomotor activity across all days of 
testing compared to other groups.  This effect was more prominent in males than in females. 
After sensitization, cerebrospinal fluid was taken via microdialysis from the nucleus accumbens 
core and was analyzed for dopamine content. Analysis revealed D2 priming produced a 300% 
increase of dopamine release in the nucleus accumbens core in response to amphetamine 
compared to controls. These results suggest that increases in D2 sensitivity may lead to increased 
reaction to amphetamine in psychotic individuals. 
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 CHAPTER 1 
INTRODUCTION 
 Individuals afflicted with schizophrenia exhibit a range of behavioral malfunction 
including, but not limited to paranoia, disruption and disorganization of regular thought patterns, 
inappropriate perception, hallucinations, and flattened affect (Spitzer, Weisbrod, Winkler, & 
Maier, 1997; Wilson, Sanyal, & Van Tol, 1998).  The schizophrenic population also abuses 
psychostimulants at a significantly higher rate than the general population (LeDuc & Mittleman, 
1995).   Current estimates suggest the incidence of psychostimulant abuse by schizophrenics to 
be anywhere from 55%-85% (Sacco et al., 2005).  When compared to the general population, 
which demonstrates a 7.5% rate of abuse (LeDuc & Mittleman), the incidence of 
psychostimulant abuse is found to be between 7-12 times higher in the schizophrenic population.  
The prevalence of psychostimulant abuse is also much higher among schizophrenics when 
compared to populations with other mental health diagnoses, which may indicate a tendency 
towards drug abuse resulting from the specific pathology of the disease itself (Richard, Liskow, 
& Perry, 1985).  This interpretation is strengthened by subsequent research suggesting that 
schizophrenics preferentially abuse drugs with stimulant properties rather than drugs with non-
stimulant properties such as alcohol, opiates, or barbiturates (Dixon, Haas, Weiden, Sweeney, & 
Frances, 1990; Schneier & Siris, 1987; Zemishlany, Aizenberg, Weiner, & Weizman, 1996).  
Clinical Consequences of Substance Abuse in Schizophrenia 
 Psychostimulant abusing individuals suffering from schizophrenia face more severe 
consequences when compared to nonabusing schizophrenics.  Most notable is an increase of the 
positive and negative symptoms inherent in the disease pathology namely psychosis, anhedonia, 
and cognitive impairment (Jeste, Gladsjo, Lindamer, & Lacro, 1996).  In addition, schizophrenic 
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 abusers of psychostimulants demonstrate a much higher incidence of suicidal ideation with 
associated depression upon admission to the hospital (Seibyl et al.). It has been demonstrated that 
substance-abusing schizophrenics tend towards more hospitalizations over the course of their 
lifetime compared to those reporting no substance abuse (Brady, Casto, Lydiard, Malcolm, & 
Arana, 1991).  The symptoms of schizophrenic patients lacking an accurate medical history of 
drug abuse are often misclassified and mistreated by health professionals, leading to a much 
poorer course of treatment and subsequent exacerbation of disease psychopathology (Seibyl et 
al.).  This outcome is likely due to the findings that self-administration of psychostimulant drugs 
worsening psychotic symptoms that persist for longer than the half-life of the drug (Brunette, 
Mueser, Xie, & Drake, 1997; Dervaux et al., 2001). This may be the result of a persistent 
dysregulation of mesolimbic dopamine repeatedly observed in psychostimulant abuse (Koob et 
al., 2004) affecting the already increased dopamine concentrations of schizophrenic individuals 
(Heinz, 2000).    
Gender Differences in Schizophrenia 
 Gender differences play a significant role in determining the course and symptoms 
manifested in  schizophrenia.  Currently, the most clearly illustrated differences are the age of 
the individual’s first schizophrenic episode (Szymanski et al., 1995) and the severity of 
impairment as related to overall functioning (Goldstein, 1988; Goldstein & Link, 1988; 
McGlashan & Bardenstein, 1990).  Specifically, schizophrenic women demonstrate a later age of 
onset (Szymanski et al.) and much higher capacity for overall functioning than schizophrenic 
men (Goldstein & Link, ; McGlashan & Bardenstein).  Women also demonstrate increased 
responsiveness to neuroleptic medication used to treat the disease (Szymanski et al.), which is 
congruent with the finding that schizophrenic women require less frequent hospitalization, and 
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 they are hospitalized for shorter periods of time (Goldstein).  Women are also less vulnerable to 
paranoia and hallucinations while demonstrating a higher ability for interpersonal psychosocial 
functioning than men (Andia et al., 1995) who demonstrate more negative symptoms such as 
flattened affect and cognitive deficits of greater severity compared to affected women 
(Szymanski et al.). 
 Thus far, it is unclear if gender differences play as strong of a role in the interaction 
between schizophrenia and habitual drug abuse.  Initial studies have indicated that substance 
abusing schizophrenic women lose their capacity for higher functioning and become statistically 
identical to abusing schizophrenic males as indicated by similar scores on the Global Assessment 
of Functioning (Gearon & Bellack, 2000). In accord with clinical observations, there is also 
experimental evidence to suggest that schizophrenic women may be differentially vulnerable to 
negative effects of substance abuse (LeDuc & Mittleman, 1995).  
A Rodent Model of Schizophrenia 
 Animal models have been useful in developing numerous experimental treatments while 
minimizing the risk of implementing these treatments in a clinical setting.  However, due to the 
complexity and limited understanding of the etiologies of mental illnesses, appropriate animal 
models have been difficult to develop. But, as new light shed is on these disorders, researchers 
have been able to accurately model diseases such as schizophrenia bringing about disease 
specific behavioral abnormalities by inducing specific neurological abnormalities found in 
individuals with the disorder.  Still, it remains important that these induced neurological 
abnormalities be similar to those found in the clinical population as to allow for the development 
of realistic treatments.  
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  Acute drug induced model of schizophrenia.  In schizophrenia, hyperactivity of the 
dopamine neurotransmitter system has been widely proposed as the neurochemical culprit.  
Several rodent models have attempted to model dopaminergic hyperactivity via pharmacological 
intervention.  One approach has been to administer a drug known to produce large increases in 
dopamine such as phencyclidine (PCP) or cocaine and then behaviorally test the animal while it 
is under the influence of these drugs (Lacroix, Broersen, Feldon, & Weiner, 2000; Tilson & 
Rech, 1973).  These models, although useful in demonstrating the effects of acute drug 
administration and subsequent hyperactivity in the dopamine system, fail to produce long-term 
dopamine hyperactivity and, thus, fail to provide a model of the developmental aspects of the 
disease.   On the other hand, these models led to some insights on the underlying mechanisms in 
schizophrenia. For example, findings using the acute drug induced model have shown that 
dopaminergic dysregulation in the medial prefrontal cortex plays a role in modulating sensory 
gating, a function that is impaired in human schizophrenics as well as in many animal models of 
schizophrenia (Lacroix et al.).   
 Neonatal ventral hippocampal lesion model.  A different rodent model of schizophrenia 
capitalizes on the decreases in synaptic connectivity in the hippocampus known to be present in 
schizophrenia (Lipska & Weinberger, 2000). In this model, the ventral portion of the 
hippocampus is ablated. The hippocampus is a region of the brain known to play a major role in 
cognitive performance. In the neonatal ventral hippocampal lesion (NVHL) model, 7-day old rats 
are administered a lesion of the hippocampus in an attempt to mimic hippocampal 
neuropathology known to exist in schizophrenia.  This model has been used to effectively test the 
social, behavioral, and cognitive impairments known to exist in schizophrenia  such as increased 
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 anxiety, social impairment, isolation, and inhibition of the startle response to a repeatedly cued 
frightful stimulus (Sams-Dodd, Lipska, & Weinberger, 1997).   
Although this model has shown several consistencies with the disorder, it remains that 
there has been no definitive evidence to suggest incidence of cell death in the hippocampus of 
schizophrenics (Harrison, 2004; Harrison & Eastwood, 2001) despite evidence of extensive 
anomalies in the synaptic development of hippocampal neurons (Harrison, 1999).  Also, it 
remains to be determined as to what extent other regions of the brain may be damaged in 
producing this model of schizophrenia as well as whether or not the behavioral deficits witnessed 
might be due to collateral damage in other brain regions. 
 Disrupted in schizophrenia 1 transgenic mouse model.  Newly developed transgenic mice 
models could be valuable thanks to their ability to model mental illnesses at the genetic and 
developmental level where many mental illnesses are thought to originate.  The Disrupted in 
Schizophrenia 1 (DISC1) protein knockout or transgenic mouse model manipulates the 
expression or functionality of a genetic transcript that has been repeatedly found disrupted in 
individuals with schizophrenia or related disorders such as schizoaffective disorder, bipolar 
disorder, and recurrent major depression (Millar, Wilson-Annan, et al., 2000).  The DISC1 
protein disruption, only recently reported in 2000, is thought to affect genetic expression in 
multiple locations such as the heart, kidneys, testis, and placenta but maintains the highest 
transcript concentrations in the brain, specifically in the dentate gyrus and CA1-CA3 regions of 
the hippocampus (Millar, Christie, Semple, & Porteous, 2000).  The DISC1 mouse model of 
schizophrenia shares multiple anatomical anomalies repeatedly demonstrated in human 
schizophrenics, most notably decreased connectivity in the hippocampus without cell death as 
well as enlarged lateral ventricles.  Behaviorally, DISC1 disrupted mice demonstrate some 
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 clinically relevant correlates, such as small disturbances in sensory gating (Hikida et al., 2007) 
and impairment of working memory in a match-to-place task (Koike, Arguello, Kvajo, 
Karayiorgou, & Gogos, 2006). 
This model demonstrates a potentially useful new approach to the study of schizophrenia.  
However, it must be noted that this model is relatively new and untested.  For instance, although 
multiple anatomical correlates exist between the model and the clinical population, it is, as of 
yet, unreported to what extent other anomalies exist in the brain tissue of DISC1 knockouts and 
mutants.  Also, although deficits in sensory gating are reported, it must be noted that published 
reports of such deficits are not nearly as robust as seen in other models as they were limited to 
one level of the prepulse and were not significant on any other level of testing (Hikida et al.).  
However, reported unpublished data may report more robust PPI deficits that have been 
demonstrated in other more prevalent models (Ishizuka, Paek, Kamiya, & Sawa, 2006). 
 D2 receptor priming model.  The abnormal behaviors observed in schizophrenia relate to 
increased activity of the dopamine D2 receptor (Crow, 1979; Davis, Kahn, Ko, & Davidson, 
1991).  This effect is akin to the action of drugs that produce similar symptoms in humans 
(Castaneda, Becker, & Robinson, 1988; Kokkinidis & Anisman, 1980). All antipsychotic drugs 
used to treat schizophrenia block the D2 receptor with some affinity (Tollefson, 1996). The drug 
quinpirole, a drug that serves as an agonist to D2/D3 receptors, has been shown to produce 
hyperactivity of the D2 receptor when administered to rats postnatally between days 1-11, 1-21, 
or 21-35, and this increase in D2 sensitivity has been shown to persist throughout the animal's 
lifetime.  This phenomenon  is known as 'D2 priming' (Kostrzewa, 1995; Kostrzewa, Brus, 
Rykaczewska, & Plech, 1993; Kostrzewa, Guo, & Kostrzewa, 1993).  The neurochemical 
pathology of schizophrenia, however, does appear to be more complex than just changes in the 
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 D2 receptor and involves several other neurotransmitter systems such as acetylcholine, serotonin, 
and glutamate (Harrison, 1999; Iqbal & van Praag, 1995; Lipska & Weinberger, 2000) 
Additionally, schizophrenics demonstrate significant increases in glucocortocoid hormones 
(Cotter & Pariante, 2002). 
Regardless of the model’s focus on a single neurotransmitter system, there are several 
consistencies of the D2 priming model with behavioral deficits in schizophrenia. First, studies 
using Positron Emission Tomography (PET) have illustrated robust increases of dopamine 
release in the striatum of human schizophrenics exposed to amphetamine (Abi-Dargham, 1999) 
or  methamphetamine (Lavalaye et al., 2001). Consistent with these results,  MRI and Magnetic 
Resonance Spectroscopy (MRS) results have demonstrated increased D2 receptor density 
(Soares & Innis, 1999). These effects have been mimicked in the D2 primed rat using in vivo 
microdialysis, a technique that involves taking measurements of cerebrospinal fluid from the 
striatum of a live rat.  Results have shown that D2 primed rats experience a 5-fold increase of 
dopamine in the dorsal striatum when administered an acute injection of d-amphetamine using 
the microdialysis technique, which is similar to past findings in schizophrenics (Nowak, Brus, & 
Kostrzewa, 2001).  
Priming of the D2 receptor through neonatal treatment with quinpirole in the rodent has 
also been shown to be at least somewhat consistent with deficits in sensorimotor gating in 
schizophrenics. Sensorimotor gating can be measured through a behavioral task called prepulse 
inhibition (PPI). In this test, the subject is presented with a nonstartling auditory stimulus (known 
as the prepulse) that is followed shortly after by a much louder auditory stimulus (known as the 
pulse) intended to startle the animal or subject. The prepulse should come to predict the pulse, 
and thus, the animal should demonstrate an inhibition in the startle response when the prepulse is 
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 administered. Research has shown that schizophrenics demonstrate approximately a 50% 
decrease in prepulse inhibition (Braff, Geyer, & Swerdlow, 2001). In our laboratory, we have 
shown that D2-primed rats demonstrate approximately a 20%-25% decrease in prepulse 
inhibition depending on the auditory intensity of the prepulse (Maple et al. manuscript in 
preparation). Although this is somewhat inconsistent with findings in schizophrenics, it remains 
that D2-primed rats demonstrate a significant PPI deficit, and it could be that increases in 
sensitivity of the D2 receptor contribute approximately half of this deficit, with the other half 
accounted for by other changes in brain function such as changes in acetylcholine (Crook, 
Tomaskovic-Crook, Copolov, & Dean, 2001; Leonard et al., 2002), glutamatergic (Harrison, 
2004), or serotoninergic systems (Iqbal & van Praag, 1995). Current research has repeatedly 
demonstrated that activation of the D2 receptor produces subjects that are significantly slower 
than normal controls in their ability acquire sensory gating (Kumari & Sharma, 2002), and it 
appears that the D2 receptor plays a more important role in PPI as compared to the D1 receptor 
(Geyer, Krebs-Thomson, Braff, & Swerdlow, 2001). 
Several studies have reported severe cognitive deficits in schizophrenia such as impaired 
sustained attention or vigilance (Green, 1996), dysfunction of verbal (Fleming, Goldberg, Gold, 
& Weinberger, 1995) and visio-spatial (Keefe, Lees-Roitman, & Dupre, 1997; Park & Holzman, 
1992) working memory, verbal learning (Green, Kern, Braff, & Mintz, 2000), problem solving 
(Bustini et al., 1999), and social cognition (Silver & Shlomo, 2001). Occurrence of these deficits 
are so consistently manifested that many posit them as the core symptoms of schizophrenia 
(Elvevag, Egan, & Goldberg, 2000).   
Using the D2 priming model, similar cognitive deficits have been demonstrated in rats 
(Brown et al., 2002, 2004, 2005; Thacker et al., 2006).  Specifically, these studies have  
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 demonstrated deficits in spatial memory as demonstrated by differential performance on the 
Morris Water Maze (MWM) task as compared to controls.  In this task, animals are placed in a 
pool of black colored water and there is a small platform hidden located slightly beneath the 
surface of the water that allows the rat to exit the aversive water environment. After multiple 
training trials, saline treated controls repeatedly outperform D2 primed rats in on the probe trial 
given at the end of acquisition as well as on the working memory version of the task, known as 
the match-to-place version  (Brown, Flanigan et al., 2004; Brown, Gass, & Kostrzewa, 2002; 
Brown, Thompson et al., 2004).   
The evidence for D2 priming as a rodent model of schizophrenia is bolstered by the 
findings that drugs intended to alleviate cognitive deficits in human schizophrenics by blocking 
D2 hyperactivity also produce similar effects in the D2 primed rat.  More recent work has shown 
that the atypical antipsychotic olanzapine alleviated the spatial memory deficits of D2 primed 
rats.  Additionally, olanzapine also eliminated the significant increase in yawning produced by 
D2 priming with quinpirole, essentially reversing D2 hyperactivity (Thacker et al., 2006).  
Finally, olanzapine was also shown to significantly alleviate significant decreases in 
neurotrophic factors in the hippocampus produced by priming of the D2 receptor, suggesting a 
significant effect of this drug on neuroplasticity in the hippocampus that may be underlying these 
deficits. Therefore, it appears that antipsychotic drugs are effective at alleviating behavioral 
deficits and changes in neurochemistry related to brain plasiticity produced by priming of the D2 
receptor.  
Finally, there are also data to demonstrate the presence of numerous neurochemical 
anomalies in D2 primed rodents that are also present in human schizophrenics.  First, D2 priming 
has been shown to produce a 36% decrease in choline acetyltransferase (ChAT) as well as a 
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 significant decrease in nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) 
in the hippocampus compared to saline controls (Brown, Flanigan et al., 2004; Brown, 
Thompson et al., 2004).  These results agree with research that has indicated that nerve growth 
factor is also significantly decreased in nonmedicated human schizophrenics, which has been 
suggested to account for the multiple neurodevelopmental abnormalities caused by the disease 
(Aloe, Iannitelli, Angelucci, Bersani, & Fiore, 2000; Parikh, Evans, Khan, & Mahadik, 2003).  
The former findings of decreased ChAT from D2-primed rodents may also demonstrate 
congruence with human studies in that human schizophrenics exhibit decreases in density of the 
alpha4beta2 nicotinic receptor in the hippocampus (Durany et al., 2001), the alpha7 nicotinic 
receptor subunit gene (Leonard et al., 2002), and the muscarinic receptor (Raedler et al., 2003), 
which may be due to down regulation of these receptors when acetylcholine synthesis is reduced.  
An Animal Model of Substance Abuse:  Sensitization 
 The term behavioral sensitization is a learning phenomenon defined as increases in 
responding to repeated presentations of a stimulus.  In drug abuse, behavioral sensitization is 
thought to underlie mechanisms of addiction (Robinson & Berridge, 1993) and is typically 
manifest as an augmented behavioral response following repeated presentations of the drug 
(Kalivas, Pierce, Cornish, & Sorg, 1998).  Research has shown that modifications in dopamine 
function is critical for sensitization to several psychostimulants including amphetamine, nicotine, 
and cocaine (Kalivas & Duffy, 1993; Kalivas, Sorg, & Hooks, 1993; Vanderschuren & Kalivas, 
2000).  Specifically, increased in dopaminergic fucntion in the mesocorticolimbic pathway has 
been hypothesized to play a significant role in behavioral sensitization (Kalivas et al., 1993).  
 The mesocorticolimbic pathway begins in the ventral tegmental area of the midbrain from 
which it projects to the prefrontal cortex and the ventral region of the basal ganglia.  Structures 
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 receiving connections from the latter region of the pathway, the nucleus accumbens core and the 
ventral striatum,  appear to play significant roles in induction of behavioral sensitization (Kalivas 
et al., 1993). Studies have demonstrated increased dopamine function in these areas in vivo and 
in vitro following repeated administrations of d-amphetamine (Castaneda et al., 1988; Kolta, 
Shreve, De Souza, & Uretsky, 1985) as well as localized infusions of d-amphetamine into the 
nucleus accumbens of previously sensitized animals (Pierce & Kalivas, 1995). Previous 
microdialysis studies investigating the effect of d-amphetamine have demonstrated a two-fold 
increase in dopamine concentration in the nucleus accumbens core when compared to the shell 
following acute administrations of the drug (McKittrick & Abercrombie, 2007), a structure 
thought to underlie reinforcement and learning. This result is consistent with findings from self-
administration studies, which have likewise demonstrated significant increases in extracellular 
dopamine levels in the nucleus accumbens following self-administration of d-amphetamine (Di 
Ciano et al., 1995).  
 The nucleus accumbens alone, however, is not solely responsible for sensitization on the 
cellular level.  It has been demonstrated that the actions of dopamine cell bodies in the ventral 
tegmental area are necessary and sufficient for amphetamine sensitization while actions of 
dopamine cell bodies in the nucleus accumbens are not sufficient to produce an increased cellular 
response for locomotor sensitization.  However, the nucleus accumbens is necessary for the 
behavioral induction, or expression of sensitization (Cador, Bjijou, & Stinus, 1995; Hooks, 
Jones, Liem, & Justice, 1992), demonstrating the importance of this area in amphetamine-
induced behavioral sensitization.  
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 Dopamine Receptors: Their Involvement in Behavioral Sensitization to Psychostimulants  
Two dopamine receptor families have been identified in the central nervous system.  The 
D1-like family includes the D1 and D5 subtypes, whereas the D2-like family includes the D2, 
D3, and D4 subtypes. Both families of receptor are slow-acting, metabotropic receptors, meaning 
binding of these receptors initiates a G-protein- mediated biochemical cascade that, in turn, 
affects cellular communication. This class of receptor contrasts the actions of fast synaptic or 
ionotropic receptors that immediately change their conformation upon binding of the appropriate 
ligand (Girault & Greengard, 2004).   
Although data have determined the importance of dopamine to behavioral sensitization 
(Vezina & Queen, 2000; Vezina & Stewart, 1989), it remains unclear as to exactly which 
receptor family plays the larger role. According to the majority of evidence, the D1 receptor 
seems to play a bigger role in behavioral locomotor sensitization to amphetamine than the D2 
receptor, an effect that has been demonstrated by attenuation of amphetamine sensitization via 
blockade of the D1 receptor (Drew & Glick, 1990).  Concurrently, D1 receptor knockout mice 
failed to exhibit sensitization to amphetamine (Karper et al., 2002).  Additionally, blockade of 
the D1 receptor by the D1 receptor antagonist SCH-23390 blocks sensitization to amphetamine 
while other antagonists known to have a greater affinity for the D2 receptor subtypes do not 
produce similar results (Vezina, 1996). Signaling by the D1 receptor subtype has been shown to 
be directly altered during behavioral sensitization to amphetamine evidenced by its increased 
sensitivity to amphetamine as measured by electrophysiological recordings as well as the 
differential genetic expression that is dependent upon induction by the D1 receptor, specifically 
Fos, FosB, and JunB (Hu et al., 2002).     
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 However, pharmacological blockade of two D2 receptor subtypes, specifically the D3 
and D4, have also been shown to attenuate sensitization and dopamine release (Chiang, Chen, & 
Chen, 2003; Feldpausch et al., 1998), but these effects appear to be much more secondary to the 
role of the D1 receptor.  For example, studies have demonstrated that high doses of the D2 
receptor antagonist eticlopride are sufficient to block locomotor sensitization, whereas pre-
exposure to low doses of eticlopride actually produced enhanced activity following exposure to 
amphetamine.  This effect could be due to elevation of extracellular dopamine levels in the 
ventral tegmental area induced by low dose eticlopride (Tanabe, Suto, Creekmore, Steinmiller, & 
Vezina, 2004).  It has also been hypothesized that the D3 receptor subtype may play a role in 
inhibiting locomotor induction, but increased and repeated binding of these receptors may, in 
turn, produce tolerance of these effects in the cell.  So, as the D3 receptor becomes tolerant to 
amphetamine, less inhibitory effects are produced, which may indirectly induce locomotor 
sensitization (Richtand et al., 2000).  
Sex Differences and the Estrus Cycle and its Relationship to Psychostimulant Sensitization 
 There are considerable data to suggest that sex plays a substantial role in differential 
biological responses to psychostimulants in sensitization of psychomotor behavior (Becker, 
1999; Bowman et al., 1999; van Haaren & Meyer, 1991).  Female rats chronically exposed to 
amphetamine or nicotine exhibit significantly greater locomotor activity when compared to 
comparably exposed males (Becker; Booze, Wood, Welch, Berry, & Mactutus, 1999; Melnick & 
Dow-Edwards, 2001).  Additionally, female rats have been shown to demonstrate  a significantly 
greater stereotypical behavior such as yawning and chewing (Beatty & Holzer, 1978) as well as 
rotational behaviors compared to males when receiving amphetamine (Robinson, Becker, & 
Ramirez, 1980).   
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 It has been suggested that sex differences may occur as a result of the response of 
dopamine to ovarian hormone fluctuation during the estrous cycle.  In rats, the estrus cycle lasts 
for approximately 4 days, passing through three stages: Diestrus, Proestrus, and Estrus (Butcher 
& Kirkpatrick-Keller, 1984).  It is empirically possible to define this by swabbing vaginal cells 
and examining these cells microscopically.  During the 36 hours of vaginal estrus, the epithelial 
cells are seen to be cornified, meaning they have accumulated keratin and died.  Under a 
microscope, these cells appear larger and rectangular in shape.  Estrus is followed by a period of 
time in which the number of cornified cells drops, which is termed vaginal diestrus.  This stage 
lasts 2 days, which are termed diestrus stage I and diestrus stage II respectively.  After diestrus 
the number of nucleated cells in the vaginal epithelium increases in comparison to the cornified 
cells.  This stage is known as vaginal proestrus, which is the stage corresponding to behavioral 
estrus.  During this 12-hour period, estrogen levels increase and the animal begins to exhibit 
estrus behavior.  
 Studies have shown that, during this period, females rats are much more sensitive to the 
effects of amphetamine, both chemically and behaviorally.  For example, when the dopamine 
system in the striatum is stimulated during behavioral estrus, female rats exhibit much greater 
dopamine-associated behaviors, such as rotational behavior, grooming, head-bobbing, and 
forelimb movements, in comparison to diestrus I (Becker & Cha, 1989; Becker, Robinson, & 
Lorenz, 1982; Kalivas & Stewart, 1991; Robinson et al., 1980).  It is believed that estrogen acts 
to increase calcium currents in striatal neurons.  This, in turn, decreases GABA release bringing 
about a decreased inhibitory response of dopamine terminals.  As a result, dopamine release, 
metabolism, and reuptake is enhanced indicating greater dopamine activity (Becker, 1999; 
Robinson et al.). 
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 The enhanced dopamine function in females that is augmented during the estrus cycle 
prompts locomotor activity to a greater degree than is found in male rats. For example, research 
has demonstrated that females are more behaviorally sensitive to activation of the D1 receptor, 
whereas males are more sensitive to activation of the D2 receptor.  The effects of these different 
receptors leads to locomotor activation in the female rat, which contrasts the locomotor 
depression seen in males (Schindler & Carmona, 2002).  Additionally, when male and female 
rats were injected with a D1 agonist there was a period of locomotor depression followed shortly 
after by a period of locomotor activation.  In this particular study, it was found that males 
seemed to be much more sensitive to the period of locomotor depression whereas females 
demonstrated a much greater period of subsequent locomotor activation (Heijtz, Beraki, Scott, 
Aperia, & Forssberg, 2002).  Ultimately, it can been concluded that females are more sensitive to 
locomotor stimulation brought about via activation of the D2 receptor (Frantz & Van 
Hartesveldt, 1999; Szumlinski, Goodwill, & Szechtman, 2000).  Accordingly, females who 
receive amphetamine demonstrate increased activity due to the agonizing effects of amphetamine 
on the dopamine system (Camp & Robinson, 1988; Forgie & Stewart, 1993). 
Microdialysis Technique 
 In vivo microdialysis is a useful technique for measuring concentrations of many 
substrates in the brain of an awake, behaving animal.  Recently, microdialysis was used to 
measure dopamine concentrations of D2 primed animals following acute administration of 
amphetamine.  In this study, D2 primed animals demonstrated a 5-fold increase in striatal 
dopamine concentration following a single dose of amphetamine (Nowak et al., 2001).   
 Based on the tenets of sensitization previously addressed, these increases should become 
even more robust following repeated administrations of amphetamine.  This sort of interaction 
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 may convey additional vulnerability to psychostimulant addiction as seen in the schizophrenic 
population.  Additionally, these results were found in the striatum, an area of the brain primarily 
associated with regulation of motor function that is influenced by other areas more closely 
associated with learning and reinforcement such as the nucleus accumbens.  So, it is possible that 
the increases in dopamine concentration may be even more robust in brain areas directly related 
to learning and reinforcement.     
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 CHAPTER 2 
METHODS 
Collection of Preliminary Data 
 Treatment groups.  Eight research groups were used for this study, each group being 
comprised of 6-9 male or female Sprague-Dawley rats that were the offspring of timed female 
dams (Harlan, Indianapolis, IN).  
 All groups received neonatal injections from postnatal days (P) 1-11 with either saline or 
the D2/D3 agonist quinpirole.  During behavioral sensitization and microdialysis, animals were 
given ip injections of either saline or d-amphetamine. The experimental design is  outlined in 
Table 1 
Table 1. 
Combinations of Sex, Model, and Sensitization Treatments 
 
 
 
 
 
 
 
 
 
  
Number of Animals Sex Neo-Natal Treatment Sensitization Treatment 
8 Male Quinpirole Saline 
8 Male Quinpirole d-Amphetamine 
8 Male Saline Saline 
8 Male Saline d-Amphetamine 
8 Female Quinpirole Saline 
8 Female Quinpirole d-Amphetamine 
8 Female Saline Saline 
8 Female Saline d-Amphetamine 
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  Neonatal injections.  Neonatal injections began on P1, the day following birth, and given 
each day through P11. All animals received an interperitoneal (i.p.) injection of either 1 mg/kg 
quinpirole or saline at 1% of the treatment group’s average weight.  Following injection, the 
needle remained in the peritoneal cavity for 3-5 seconds to allow for proper absorption of the 
drug, avoiding possible capillary action generated by withdrawal of the needle. 
 At postnatal day 21, animals were weaned, socially housed, and then raised to adulthood 
(P60).  At P60 D2 receptor priming was verified by testing for increased yawning behavior 
(Cooper, Rusk, & Barber, 1989).  Prior to testing, each animal was administered an acute i.p. 
injection of 100 μg/kg quinpirole and then placed in an inverted cage without bedding as the 
presence of bedding can induce chewing and nesting behaviors that can supercede yawning.  An 
observer then recorded yawning activity of each rat for a period of 1 hour. 
 Behavioral Sensitization.  On the day following the yawning procedure, animals began 
amphetamine sensitization. During sensitization testing, locomotor activity was tracked every 
other day for a total of seven exposures to amphetamine or saline.  The rationale for using an 
intermittent sensitization paradigm is based on past studies that have shown repeated intermittent 
exposure to psychostimulants produces long-term enhancements in the ability of 
psychostimulants to produce increases in locomotion as compared to saline controls (Robinson & 
Camp, 1987; Saito et al., 2005; Steketee, 2005).   
Before each session animals were weighed and injected i.p. with either saline or d-
amphetamine (1.0 mg/kg).  Approximately 10  minutes after the injection, animals were placed 
into one of four identical 15”x15” plywood boxes interiorally painted black to allow for 
necessary contrast between the white animal and the floor of the apparatus as needed for 
behavioral tracking with Anymaze Digital Tracking software (Stoelting Inc., Wood Dale, IL).  
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 Before sensitization testing, all animals were given four drug free 10 minute trials to habituate to 
the sensitization arena and injection procedures, thus preventing any effects of novelty on 
behavioral measures.  Approximately 10 min before each habituation trial, all animals were 
given an injection of saline, which was done to habituate animals to the injection itself.  All 
behavioral testing trials were digital video recorded and all movements were analyzed using the 
Anymaze software program. Locomotor activity was recorded as the number of line crosses by 
each animal, as a grid was superimposed on the digital video file by the software. Other 
measures of stereotypic behavior, immobility and rotational spinning behavior, were measured 
and compared for directionality of spinning. 
 Explanation of dependent measures.  Horizontal activity is the first dependent measure 
under analysis in this study and is the most common dependent measure in studies analyzing 
locomotor sensitization.  When the animal is placed into the locomotor arena, the AnyMaze 
software program digitally superimposes a 5 x 5 cm grid across the floor of the apparatus.  Each 
time the animal crosses a line of the grid AnyMaze, this even is recorded as an activity count.  
The total line crosses for each trial provide a quantification of horizontal activity.  The total 
number of horizontal activity counts were averaged across subjects within each group on each 
day of drug administration..  However, this measure can reach a point of diminishing returns.  If 
dopamine activation is high enough, the animal may enter stereotypy in which behaviors such as 
chewing, grooming, and paw treading supercede locomotion.  In this case, the animal is recorded 
as being immobile.  Therefore, measures of stereotypy and immobility will be considered as 
well.   
 Path stereotypy is the second behavioral dependent measure under analysis in this study. 
This is another measure of possible dopamine activation.  AnyMaze can record 360˚ rotations 
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 made by each animal..  The total number of clockwise and counterclockwise rotations executed 
by each animal were summed together to compose a variable we referred to as path stereotypy. 
This is a measure of stereotypic behavior that has also been referred to as checking behavior. 
Checking behavior is a compulsive stereotypic behavior that is a ritual-like motor activity pattern 
that has been related to increases in dopamine function, especially increases of dopamine D2 
receptor activation (Szechtman et al., 2001; Szechtman & Woody, 2004).  
 The amount of time spent immobile is the third behavioral dependent measure under 
analysis. AnyMaze records this event as any time the animal fails to cross a line on the digital 
grid for a period to 2 seconds.  After the 2-second interval, AnyMaze records the time until the 
next line crossing.  This time between the 2-second interval and the next line crossing is time 
spent in immobility. Although this is essentially the opposite dependent measure as horizontal 
activation, it does have some unique properties. First, through observation, we have noted that 
when rats stop moving in the locomotor arena, they typically begin participating in behaviors 
that have been referred to as stereotypic behaviors such as grooming, paw treading, or vertical 
rearing. Increases in any of these behaviors has been related to increases in general dopaminergic 
function (Beninger, Mazurski, & Hoffman, 1991). Second, we have also noted that immobility 
time and horizontal activity are not necessarily inversely related; in other words, group 
differences in horizontal activity does not necessarily indicate group differences in immobility 
time, suggesting these two behavioral measures are independent.  
 Verification of estrus cycle.  On each day of testing, stage of estrus cycle of female rats 
was verified. A sample of cells were taken from the animal’s vaginal lumen using a moistened 
cotton swab.  The sample was then smeared onto a slide and placed under a microscope 
(Olympus microscope BH series) for analysis. The stage of the estrous cycle was statistically 
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 correlated with the behavioral testing and dopamine release on the amphetamine challenge to 
determine if the stage of the estrous cycle interacted with locomotor activity and/or dopamine 
release under the influence of amphetamine. 
 Statistical analysis.  Analysis of Variance (ANOVA) was the primary statistical test and 
Fisher’s Least Significant Difference test will serve as the post hoc test. Alpha-level was set at 
.05 for all analyses. For analysis of behavioral sensitization and dopamine release on the 
amphetamine challenge, the design consisted of three independent variables: Sex (Between 
subjects, 2 levels: Male, Female), Neonatal Drug Treatment (Between subjects, 2 levels: 
Quinpirole and Sal), and Adulthood Drug Treatment (Between subjects, 2 Levels: Sal-Amph, 
Sal-Sal). Days 1 and 7 will be analyzed separately to insure a significant change in activity over 
days of sensitization training by using a repeated measures ANOVA using days 1 and 7 as the 
level of a fourth IV.   
Preliminary Data 
 A 2 x 2 x 7 three-way ANOVA revealed a significant adulthood drug treatment main 
effect F(1,35) = 9.35, p<.004, a significant two-way interaction of Adulthood Drug Treatment x 
Day of Testing F(6,35) = 4.47, p<.001, and a significant three-way interaction of Ontogenetic 
Drug Treatment x Adulthood Drug Treatment x Day of Testing F(6,35) = 3.52, p<.003 on 
rotational behavior. Group Q-A demonstrated a significant increase in activity at days 1, 4, and 5 
as compared to all other groups (indicated by **). Group S-A demonstrated a significant increase 
in activity as compared to controls at days 5-7 (indicated by *). Group S-A also demonstrated a 
significant increase in activity from day 1 to day 7, whereas Group Q-A did not, demonstrating 
that D2-primed females did not sensitize to amphetamine, whereas controls demonstrated 
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 sensitization to adulthood amphetamine treatment.  See Figure 1 for females and Figure 3 for 
males. 
  
  
    
  
 
 
 
  
 
  
  
** Q-A animals significantly different from all other groups on days 1, 4, & 5 
 
*   S-A animals significantly different from S-S on days 5, 6, & 7 
 
Figure 1:  Activity Counts are Presented as a Function of Drug Treatment Group for Females 
 _______________________________________________________________________ 
 These results indicate that although D2-primed females do not demonstrate augmented 
sensitization compared to nonprimed controls, they do exhibit robust increases in activity on the 
first day of treatment, which indicates that D2-primed subjects may be more sensitive to the 
effects of the drug when compared to nonprimed controls.  It is important to note, however, that 
these data have not yet been correlated with and corrected for the estrus cycle data, which may 
influence our results with further analysis. 
 A 2 x 2 x 7 repeated measures ANOVA revealed only a significant main effect of 
adulthood drug treatment F(1,35) = 8.56, p<.006 and a significant main effect of day of testing 
F(6,35) = 2.81, p<.012, on rotational stereotypy. Amphetamine increased path stereotypy in 
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 females as compared to saline treatment, but there were no effects of ontogenetic drug treatment.  
Again, it is important to note that the correlation of estrus data could change the significance of 
this outcome.  Additionally, as there are only 3-4 animals per treatment group, continued testing 
may help lower variability, increase statistical power, and bring out the apparent differences in 
the means.  See Figure 2. 
 
 
 
  
  
   
 
  
 
 
 Figure 2: Total Number of Clockwise and Counterclockwise Turns as a Function of Drug 
 Treatment for Females. 
 __________________________________________________________________ 
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** Q-A animals significantly different from all other groups on days 1-6 of testing 
 
* S-A animals significant from saline controls on days 3-7, Q-A also 
 significantly different from only control on day 7 
Figure 3:  Activity Counts are Presented as a Function of Drug Treatment Condition for Males. 
__________________________________________________________________ 
A 2 x 2 x 7 repeated measures ANOVA revealed a significant main effect of adulthood 
drug treatment F(1,31) = 28.62, p<.001and a significant main effect of day of testing F(6,31) = 
3.31, p<.004 and significant two-way interactions of Ontogenetic Drug Treatment x Adulthood 
Drug Treatment F(1,31)= 6.71, p<.015, and Adulthood Drug Treatment x Day of Testing F(6,31) 
= 5.14, p<.001 on male rotational behavior. Adulthood amphetamine treatment produced a 
significant increase in the path stereotypy of D2-primed males on days 1-5 and day 7, and 
amphetamine increased path stereotypy on days 4-7 in non D2-primed males but only to the 
levels of D2-primed subjects.  See Figure 4. 
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 Figure 4:  Number of Clockwise and Counterclockwise Turns as a Function of Drug 
 Treatment for Males. 
**   Q-A significantly different from all other groups on days 1-4, 7 
 
* S-A significantly different from control on days 4-7, Q-A significantly 
 different from control on days 4-5 
 
 _____________________________________________________________________ 
Discussion of Preliminary Results and Modification of Final Methods 
 Preliminary results indicate that, for both sexes, D2 primed subjects receiving 
amphetamine demonstrate significant increases in locomotor activity when compared to non-D2-
primed amphetamine controls.  Earlier literature suggests that dopamine dysregulation leads to 
the increases of extracellular dopamine that underlie such robust increases in locomotor activity 
(Kalivas & Duffy, 1993; Kalivas et al., 1998; Kalivas et al., 1993; Nowak et al., 2001).  
Interestingly, however, males demonstrate higher activity overall.  This may indicate that either 
males are more sensitive to the behavioral effects of amphetamine, contradicting a substantial 
amount of earlier literature (Becker, Molenda, & Hummer, 2001; Booze et al., 1999) or females 
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 are differentially affected by amphetamine to the extent that they reach a high level of stereotypy 
(Melnick & Dow-Edwards, 2001) that may be superceding horizontal activity. 
 The results of the path stereotypy data seem to implicate the former of these possible 
outcomes, as D2 primed males demonstrate a significantly higher number of rotations compared 
to nonprimed controls while females are not statistically increased on the same measure.  This 
result, again, contradicts previous literature that suggests females are more prone to demonstrate 
stereotypic behavior (Melnick & Dow-Edwards, 2001).  However, it is important to note that 
procedures by Melnick used cocaine, not amphetamine.  So, it is possible that amphetamine is 
inducing such a high dopaminergic response in female subjects that the behavioral response is 
reaching a point of diminishing returns.  That is, female subjects are spending much more time 
immobile while performing other superceding behaviors such as head bobbing, chewing, paw 
treading, and licking, that are not able to be tracked using digital methods.  Microdialysis 
procedures will be used to measure changes in dopamine release. 
 Experimental hypotheses.  Based on the rationale above, I hypothesize that D2 primed 
subjects show higher extracellular levels of dopamine as compared to nonprimed controls also 
receiving amphetamine.  Additionally, I hypothesize that females will demonstrate increased 
levels of extracellular dopamine in comparison to male subjects as previous literature would 
suggest.  In order to verify the validity of our female behavioral results, data for time spent in 
immobility as well as total number of immobile episodes during the sensitization procedure were 
gathered and analyzed.  I hypothesize that, in addition to D2 primed animals spending less time 
in immobility, females will spend more time, overall, in immobility as compared to male 
subjects, which would help to explain the lower level of horizontal and rotational activity seen 
for females in the preliminary data.  See Tables 2 and 3 for treatment groups.   
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  Surgical implantation of the guide canula.  On the day following the final amphetamine 
or saline sensitization trial, each animal was anesthetized using a 60% to 40% solution of 
ketamine (100 mg/kg) and xylazine (10 mg/kg).  Once the animal was anesthetized, the head was 
shaved and the animal was placed into a stereotaxic frame (Kopf, Instruments, Tujunga, CA). 
Once in the frame, the animal’s nose was placed into a Kopf stereotaxic mask (Model 906, Kopf 
Instruments, Inc., Tujunga, CA) that was attached to a gas anesthesia machine (JD Medical VT-
100, Phoenix, AZ), which constantly delivered an isoflurane/O2 gas mixture to the animal to help 
maintain anesthesia.  A single midline scalp incision was made to expose the skull, which was 
cleaned with an alcohol wipe and dried to allow for maximal adherence of the acrylic cap.  Once 
the skull was clean, a surgical drill was mounted on the stereotaxic frame and used to penetrate 
the skull.  The drill was moved to the coordinates AP (anterior/posterior) = + 1.6 mm,  ML 
(medial/lateral) =+/- 1.2 mm. Three other shallow indentions were drilled around the skull 
penetration, and surgical screws were cemented into these indentions to serve to anchor the 
acrylic cap onto the skull.  At this point, the drill was removed and a guide canula was attached 
by a holder to the stereotaxic frame.  The canula was then lowered through the hole to the 
surface of the exposed dura matter.  The canula was then lowered ventrally 6.0 mm so that it 
would be located directly above the nucleus accumbens core.  Liquid acrylic was then placed 
onto the skull around the canula and anchor screws. The acrylic was placed so that it covered the 
screws and reached the structural plastic portion of the canula.  Once the acrylic dried, the 
incision was closed using sutures and surgical staples.   
  During the postoperative period, the animal was removed from the stereotaxic frame and 
placed onto heating pads in a bedding free cage.  A 10 cc subcutaneous (s.c.) of saline was 
administered along with an intramuscular (i.m.) injection of 1 mg/kg ketoprophen anti-
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 inflammatory to help with pain management. When the animals were awake and ambulatory, 
animals were returned to their home cage and allowed to recover for 6 days during which time 
they were weighed and monitored daily. 
 Microdialysis amphetamine challenge.  Seven to 10 days following surgery, the animal 
was weighed and the estrous cycle was recorded in female rats.  The stylus was then removed 
from the guide canula and the probe inserted through the guide cannula.  Once the probe was 
secured onto the guide cannula, a filtered solution of artificial cerebrospinal fluid was dialyzed 
through the probe at a rate of 2.0 μl/minute.  Samples were taken every 20 minutes and placed 
into a conical centrifuge vial along with 1 ml of 0.5 M perchloric acid that will serve to denature 
proteins that can break down the neurotransmitters targeted in this procedure.  At this point, the 
samples were placed into a -80° C freezer until which time they can be analyzed using High 
Performance Liquid Chromatography (HPLC). 
 Samples were collected in this manner for the first 2 hours of the procedure.  At the 
beginning of the 3rd hour, animals began a series of four injections of saline or d-amphetamine 
according to the treatment received during sensitization, which was given at 20-minute intervals.  
Animals receiving injections of amphetamine were dosed cumulatively starting at 0.1 mg/kg 
increasing to 0.6 mg/kg, 1.1 mg/kg, and 2.6 mg/kg over the respective 20-minute intervals.  
Samples were collected every 20 minutes over the final 3 hours of the procedure. 
 HPLC analysis of samples.  Before experimental samples were analyzed, a series of 
standards of dopamine (DA), norepinepherine (NE), DOPAC, and homovanillic acid (HVA) 
were prepared at various known concentrations to construct a standard curve from which 
concentrations of the target neurotransmitters were calculated using the equation of the curve.  
Additionally, pure standards were injected onto the column to determine the retention time of 
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 each neurotransmitter.  The samples being tested were allowed to defrost to liquid phase and 
were then pipetted into vials to be placed into an autosampler (ESA, Chelmsford, MA).  The 
autosampler then injected 40 µl of each sample onto the detection column (ESA, Chelmsford, 
MA), where the sample separated into its respective constituents that cleared the column at its 
respective retention time.  This data are represented in a spectrograph for each sample analyzed.  
The area of each target peak was compared to the standard curve to calculate concentrations of 
each target neurotransmitter.  
 Statistical analysis.  Dopamine release, as measured by HPLC was analyzed as the 
percent change above baseline for of each sample.   Locomotor activity was analyzed as line 
crossing activity across days.  A 2x2x2x7 (sex x D2 priming x adult drug treatment x day) 
ANOVA with a Newman-Keuls post hoc test was run to determine main effects, if any, on 
horizontal activity, path stereotypy, and immobility.    
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 Table 2. 
Final Numbers of Subjects in Each Treatment Condition for Behavioral Measures 
 
 
 
 
 
 
 
 
 
 
Number of Animals Sex Neo-Natal Treatment Sensitization Treatment 
9 Male Quinpirole Saline 
9 Male Quinpirole d-Amphetamine 
10 Male Saline Saline 
9 Male Saline d-Amphetamine 
11 Female Quinpirole Saline 
12 Female Quinpirole d-Amphetamine 
10 Female Saline Saline 
8 Female Saline d-Amphetamine 
 
Table 3. 
Final Numbers of Subjects in Each Treatment Condition for Microdialysis Procedure Collapsed 
Across Sex 
 
 
 
 
 
 
 
Number of Animals Neo-Natal Treatment Sensitization Treatment
13 Quinpirole Saline 
10 Quinpirole d-Amphetamine 
12 Saline Saline 
9 Saline d-Amphetamine 
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 CHAPTER 3 
RESULTS 
Amphetamine Sensitization   
 Overall horizontal activity.  In the initial analysis of each of the dependent measure, all 
independent variables were included: sex, ontogenetic drug treatment, adulthood drug treatment, 
and day of testing. If sex differences were revealed, we analyzed males and females separately. 
When no sex differences were revealed, we collapsed over the independent variable. A 2 (sex) x 
2 (neonatal drug treatment) x 2 (adulthood drug treatment) x 7 (day of testing) four-way 
ANOVA revealed significant main effects for adult drug treatment, F(1,71) = 2.89, p<.001, and 
day of testing, F(6,71) = 2.44, p<.025, three significant two-way interactions, including neoantal 
drug treatment x adulthood drug treatment, F(1,71) = 7.73, p<.007, sex x day of testing, F(6,71) 
= 2.38, p<.029, and adulthood drug treatment x day of testing, F(6,71) = 11.21, p<.001, and   a 
three-way interaction of sex x neonatal drug treatment x adulthood drug treatment F(6,71) = 
3.32, p<.003. Analysis of the main effects showed that d-amphetamine produced a significant 
increase in horizontal activity as compared to saline-treated controls, and there was a significant 
increase of horizontal activity over the 7 days of testing. Post hoc analysis of the neonatal drug 
treatment x adulthood drug treatment interaction revealed that D2-primed animals given 
amphetamine demonstrated a significant increase in horizontal activity compared to controls.  
Post hoc analysis of the sex x day of testing revealed that males demonstrated a significant 
increase in horizontal activity relative to females but only on day 6. Finally, post hoc analysis of 
the significant adulthood drug treatment x day testing interaction revealed that d-amphetamine 
produced a significant increase in activity from days 2-7.  Most importantly, analysis of the 
three-way interaction revealed that D2-primed males demonstrated a significant increased 
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 response to amphetamine as compared to all other groups. This result shows that D2-priming as 
produced by ontogenetic quinpirole treatment enhanced locomotor activation to amphetamine 
compared to nonprimed controls.  Horizontal activity is presented for females in Figure 5a and 
males in Figure 5b. 
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 (a) Females 
 
  
(b)  Males 
 
 
**  Indicates significantly greater than all other groups 
*  Indicates significantly greater than controls 
Figure 5: Activity Counts for Females 5(a) and Males 5(b) as a Function of Drug Treatment 
Group and Day of Testing.  Group Q-A exhibited significantly higher levels of horizontal 
activity than all other groups on days 1, 4, & 5 Group S-A demonstrated significantly higher 
levels of horizontal activity as compared to controls on days 2-7.  (b) Activity counts for males 
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 as a function of drug treatment and day of testing.  Group Q-A exhibited significantly higher 
horizontal activity levels as compared to all other groups on days 1-7 of sensitization testing; 
Group S-A demonstrated significantly higher levels of horizontal activity as compared to Groups 
S-S and Q-S on days 3 through 7. 
________________________________________________________________________________________________ 
 Horizontal activity, males.  Based on the significant interactions involving sex as a factor, 
males and females were analyzed separately. For males, a 2 x 2 x 7 three-way ANOVA on 
horizontal activity revealed significant main effects of adulthood drug treatment, F(1,37) = 
31.17, p<.001,  and day of testing, F(6,37) = 4.78, p<.001, as well as significant two-way 
interactions for neonatal drug treatment  x adulthood drug treatment, F(1,37) = 6.65, p<.014, and 
adulthood drug treatment x day of testing, F(6,37) = 6.11, p<.001.  Analysis of the significant 
main effects revealed that amphetamine-treated animals increased horizontal activity compared 
to saline-treated controls and there was a significant increase in activity over days of testing. 
Analysis of the significant two-way interaction of adulthood drug treatment x day of testing 
revealed that amphetamine significantly increased activity over time. Most importantly, post hoc 
analysis of the significant ontogenetic drug treatment x adulthood drug treatment interaction 
revealed that D2 primed males administered amphetamine demonstrated a significant increase in 
horizontal activity relative to all other groups, showing that D2-priming as produced by 
ontogenetic quinpirole treatment enhanced locomotor activation to amphetamine in males.  
 Horizontal activity, females.  A 2 x 2 x 7 three-way ANOVA on the horizontal activity in 
females revealed a significant main effect for adulthood drug treatment,  F(1,39) = 14.38, 
p<.001, a significant two-way interaction of adult drug treatment x day of testing, , F(6,39) = 6.0, 
p<.001, and a significant three- way interaction of neonatal drug treatment x adulthood drug 
treatment x day of testing, F(6,39) = 2.90, p<.001.  Amphetamine increased horizontal activity 
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 compared to controls Post hoc analysis of the adulthood drug treatment x day of testing revealed 
that amphetamine increased activity compared to controls throughout testing. Analysis of the 
significant three-way interaction revealed that D2 primed females administered amphetamine 
demonstrate a significant increase in horizontal activity on days 1, 4, and 5 compared to all other 
groups.  This result indicates different patterns of locomotor activation in response to 
amphetamine in males and females, with males demonstrating more overall activation on the 
horizontal activity measure than females.   
 Path stereotypy.  Path stereotypy was collapsed across sex and day of testing as no 
differences were found on these variables.  D2 primed animals given amphetamine exhibit 
significantly higher path stereotypy than all other groups.  See Figure 6. 
 
 
**  indicates significantly greater than all other groups (p<.05) 
*   indicates significantly greater than controls (p<.05) 
Figure 6: Path Stereotypy as a Function of Drug Treatment Group.  Group Q-A exhibited higher 
overall path stereotypy than all other groups; Group S-A exhibited significantly higher levels of 
path stereotypy as compared to Groups Q-S and S-S.  
______________________________________________________________________________ 
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  Overall immobility time.  Immobility time is presented as a function of drug treatment 
group in Figures 7(a) for females and 7(b) for males.  A 2x2x2x7 ANOVA including all four 
factors on immobility time revealed a significant main effect of adulthood drug treatment, 
F(1,72) = 63.81, p<.001,  significant two- way interactions for neonatal drug treatment x 
adulthood drug treatment, F(1,72) = 8.1, p<.006, adulthood x day of testing, F(6,71) = 3.39, 
p.<.003, and sex x day of testing, F(6,71) = 4.61, p<.001, as well as a significant three-way 
interaction for sex x neonatal drug treatment  x day of testing, F(6,71) = 2.95, p<.008.  Saline-
treated animals demonstrated a significant overall increase in immobility time, as was expected. 
Post hoc analyses of the significant two-way interactions revealed that D2-primed animals 
administered amphetamine were less immobile than controls,  amphetamine-treated animals 
spent less time immobile than controls on days 2 through 7, whereas males spent more time 
immobile than females on days 1 and 2 of drug treatment. Most importantly, post hoc analysis of 
the significant three-way interaction revealed that D2-primed males given amphetamine spent 
less time immobile than all other groups. Supporting the analysis of the horizontal activity data, 
D2-primed males demonstrated more locomotor activation than all other groups.  
 Immobility time, males. A 2 x 2 x 7 three-way ANOVA on male immobility time 
revealed a significant main effect of neonatal drug treatment, F(1,36) = 7.33, p<.01, adulthood 
drug treatment, F(1,36) = 55.43, p<.001, and day of testing, F(6,36) = 3.46, p<.003, and  
significant 2-way interactions of neonatal drug treatment x adulthood drug treatment, F(1,36) = 
10.88, p<.002, and adulthood drug treatment x day of testing, F(6,36) = 4.03, p<.001.  Finally, 
this analysis also revealed a significant 3-way interaction of neonatal drug treatment x adulthood 
drug treatment x day of testing F(6,36) = 2.83, p<.01.  Overall, D2-primed males and 
amphetamine-treated males spent less time immobile than male rats neonatally treated with 
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 saline or treated with saline in adulthood respectively. Post hoc analyses of the significant two-
way interactions revealed that D2-primed males given amphetamine spent less time immobile 
than all other groups, adulthood amphetamine treatment spent less time immobile than saline-
treated controls from days 2 through 7. Finally, and most importantly, D2-primed males 
administered amphetamine spent more time immobile than all other groups on days 1 through 6. 
These data reinforce the locomotor activation data that D2 primed males administered 
amphetamine demonstrate a significant increase in activity compared to all other groups 
throughout most of drug treatment, much unlike D2-primed females that demonstrated a 
different pattern of activation due to drug treatment.  See Figure 7b. 
 Immobility time, females.  Based on the fact there were several statistically significant sex 
effects, males and females were analyzed separately on immobility time.  A 2 x 2 x 7 three-way 
ANOVA on female immobility time revealed significant main effects of adulthood drug 
treatment, F(1.35) = 22.10, p<.001 and day of testing, F(6,35) = 2.17, p<.04. Overall, 
amphetamine-treated females spent less time immobile than saline-treated females, and there was 
a change in immobility time over days of testing. Although there were no significant interactions 
in females, it did appear through observation that there may be significant group differences on  
the first day of drug treatment.  Therefore, we ran an additional 2x2 ANOVA on day 1 of drug 
treatment with only neonatal drug treatment and adult drug treatment as factors and found a 
significant two way interaction of these variables, F(1,36) = 4.91, p<.033.  Thus, it was s 
determined that D2 primed females receiving amphetamine spent less time immobile than all 
other groups on the first day of adulthood drug treatment, suggesting an initial increase in 
activity in D2-primed females produced by amphetamine.  See Figure 7a. 
  
44 
 a.  Females 
 
 
b.  Males 
 
 
 
**  Indicates significantly greater than all other groups 
*  Indicates significantly greater than controls 
Figure 7: Time Spent in Immobility for Females 7(a) and Males 7(b) as a Function of Drug 
Treatment Group and Day of Testing. For females, group Q-A exhibited significantly decreased 
immobility time  compared to all other groups on Day 1, and Groups Q-A and S-A exhibited 
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 significantly less time immobile as compared to Groups Q-S and S-S on days 2 through 7.  7(b) : 
For male, Group Q-A exhibited decreased immobility as compared to all other groups on days 1-
3 and 5-7, and Group S-A demonstrated significantly less time immobile on days 3 through 7.    
  ________________________________________________________________________________ 
Dopamine High Performance Liquid Chromatography (HPLC) of Cerebrospinal Fluid 
Microdialysate 
 Dopamine release in the nucleus accumbens core is presented as a function of drug 
treatment condition in Figure 8. No statistically significant sex differences in dopamine release 
were present in these data, so data were collapsed over that factor.  A 2 x 2 x 9 three-way 
ANOVA revealed significant main effects for neonatal drug treatment, F(1,40) = 5.93, p<.019, 
and adulthood drug treatment, F(1,40) = 13.03, p<.001,as well as significant two-way 
interactions for neonatal drug treatment  x adult drug treatment, F(1,40) = 5.63, p<.022 and 
adulthood drug treatment x time, F(8,40) = 2.68, p.004.  Both neonatal quinpirole treatment and 
adulthood amphetamine treatment significantly increased dopamine release from time point 1 
through 8, as expected.  More importantly, post hoc analyses revealed that D2-primed rats 
administered amphetamine demonstrated a significant increase in dopamine release compared to  
all other groups.  See Figure 8. 
 Due to the high variability among D2 primed females receiving amphetamine, no sex 
effects were observed. However, through observation, we noticed that females demonstrated an 
absolute increase of dopamine release, and this increase was approximately 41% in D2-primed 
females administered amphetamine as compared to non D2-primed males given amphetamine, 
whereas non D2-primed females administered amphetamine demonstrated a smaller 5% increase 
in dopamine release after amphetamine treatment a compared to non D2-primed males. Although 
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 this was not a statistically significant effect, it suggests that a sex difference may exist, and 
currently, more subjects are being added to these groups to increase statistical power.   
 
 
 
 
**  indicates significantly greater than  all other groups 
*   indicates significantly greater than controls  
Figure 8: Percent Increase From Baseline Levels of Dopamine Release in the Nucleus 
Accumbens as a Function of D2 Priming and Adult Drug Treatment as Quantified by High 
Performance Liquid Chromatography. Group Q-A demonstrate a significant three-fold increase 
in accumbal dopamine release as compared to Group S-A.  Group S-A demonstrated an 
approximate 400% increase in accumbal dopamine release as compared to baseline. 
________________________________________________________________ 
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ISCUSSION 
uinpirole and A
Amphetamine   
 The result
agonist quinpirole demonstrated enhanced locomotor activation to d-amphetamine as adults. 
Additionally, priming of dopamine D2 receptors enhanced the dopaminergic response in the 
nucleus accumbens core to d-amphetamine when animals were given an amphetamine challen
7 days after sensitization testing was complete. Therefore, it appears that priming of the 
dopamine D2 receptor leads to an enhanced dopaminergic response to the psychostimula
amphetamine not witnessed in nonprimed animals in a brain area that is known to mediate th
behavioral activating effects of drugs with hedonic properties. These findings suggest that this 
enhanced dopaminergic response would lead to an increased behavioral activation in a D2-
primed system and suggesting that priming of dopamine D2 receptors could lead to a prope
to use psychostimulants such as amphetamine.  
 Behavioral measures, horizontal activity
treated with quinpirole would demonstrate an augmented behavioral response in terms of 
horizontal activity. Results supported this hypothesis in that both male and female D2-prim
animals that received amphetamine during sensitization demonstrated a significantly greater 
number of line crosses compared to all other treatment groups beginning on the 1st day of dru
exposure.  The difference between these groups later dissipates as nonprimed animals sensitize t
amphetamine.  Past research has shown that modifications in dopamine function are critical for 
sensitization to several psychostimulants, including amphetamine, nicotine, and cocaine (Kaliva
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 & Duffy, 1993; Kalivas et al., 1993; Vanderschuren & Kalivas, 2000).  Specifically, increased 
dopaminergic function in the mesocorticolimbic pathway has been hypothesized to play a 
significant role in behavioral sensitization (Kalivas et al.).  These results support the claim that 
D2 priming does indeed lead to a supersensitized response of dopaminergic neurons to a 
stimulant drug, as shown in Nowak et al., (2001), and this increase in dopaminergic funct
appears to be manifested in a significant increase in horizontal activity. 
 Path stereotypy. It was hypothesized that D2 primed animals rece
ion  
iving d-amphetamine 
 other 
wing that 
ic 
 
s time in 
onse to 
during sensitization would demonstrate a higher number of clockwise and counterclockwise 
rotations after amphetamine treatment.  The finding that D2 primed animals administered 
amphetamine exhibit significantly greater overall rotational behavior when compared to all
groups.   A significant increase in stereotypic behaviors again suggests a hyperactive 
dopaminergic response to amphetamine and support the horizontal activity data in sho
there appears to be a significantly increased behavioral activation to amphetamine in D2-primed 
animals.  (Kostrzewa, Kostrzewa, Nowak, Kostrzewa, & Brus, 2004).   The analysis of this 
particular stereotypic behavior is unique, as most studies have shown an increase in stereotyp
behaviors after dopaminergic agonists, which typically includes grooming, paw treading, and 
vacuous chewing movements. Path stereotypy is a behavior that has also been referred to as 
compulsive checking (Szechtman et al., 2001), and the increase in this behavior has also been
associated with increased dopaminergic activity and obsessive-compulsive disorder.  
 Immobility time.  It was hypothesized that D2 primed animals would spend les
immobility in response to d-amphetamine than would nonprimed animals.  These data 
demonstrate that D2 primed animals exhibit significantly less time in immobility in resp
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 amphetamine when compared to all other treatment groups.  This also supports the claim of 
increased dopaminergic activation in these animals.  
 Behavioral augmentation as a result of D2 priming.  Studies have shown that dopamine 
release in the nucleus accumbens is necessary for the behavioral reinforcement and subsequent 
induction or initiation of behavior in response to a drug (Cador et al., 1995; Hooks et al., 1992).  
More specifically, blockade of the either the dopamine D1 (Vezina & Stewart, 1989) or D2 
receptor has been shown to attenuate induction of behavioral sensitization, and it has been 
hypothesized that the D2 receptor is necessary for such behavioral expression (Chiang et al., 
2003; Feldpausch et al., 1998).  If D2 primed animals exhibit an augmented behavioral response 
when exposed to d-amphetamine, one could realistically conclude that levels of dopamine in the 
nucleus accumbens will be substantially elevated as a result of the increased activation of primed 
D2 receptors in the nucleus accumbens. Certainly, the data from microdialysis support this 
conclusion. These data are consistent with studies in both animals (Kalivas & Duffy, 1993; 
Kalivas et al., 1993; Vanderschuren & Kalivas, 2000) as well as what has been shown in human 
schizophrenics (Abi-Dargham et al., 1998; Laruelle et al., 1996).  We assume that the reinforcing 
action of the dopamine in the nucleus accumbens likely becomes much greater in these 
individuals and this is the mechanism underlying the increased abuse of psychostimulants in this 
population.  
Augmented Dopamine Release in the Nucleus Accumbens of D2 Primed Animals Given 
Amphetamine in Adulthood   
 It is thought that the key to D2 receptor supersensitivity has to do with the mechanism of 
action at the D2 receptor.  The D2 receptor is what is known as a metabotropic receptor which is 
in direct contrast to ionotropic, or fast synaptic receptors that can affect the state of a neuron 
50 
 almost instantly.   The time of action for an ionotropic receptor is, for the most part, negligible 
regarding its effect on the cell.  On the other hand, because metabotropic receptors respond to 
stimuli much more slowly, the time course of action is longer, but changes at these receptors 
often have a much greater effect on overall neuronal functioning.   
 This time course of action at metabotropic receptors is dependent upon the execution of a 
chemical reaction that occurs once the substrate binds the receptor.  In a metabotropic receptor, 
the receptor couples to a protein called the G-protein when it is bound by a substrate.  This 
protein sets off a chain of chemical reactions that, upon their completion, lead to the opening of 
the transmembrane receptor, which contributes to possible depolarization of the cell.  In each 
step of this chain reaction, certain catalysts are required to carry out the reaction while the 
presence of other proteins will regulate the reaction .  Manipulation of any of these factors could 
lead to a shift in the time-course of the g-protein coupled receptor.   
 A recent study published from our laboratory has shown that one of the regulatory 
proteins that moderates this chain reaction, RGS9, is significantly down regulated in D2 primed 
animals (Brown, Flanigan, et al., 2004; Maple, Perna, Parlaman, Stanwood, & Brown, 2007).  
RGS9 is a regulatory protein that has been shown to accelerate the termination of D2 related 
events (Kovoor et al., 2005). There is also evidence suggesting that cAMP, a catalyst in the 
second messenger cascade, is upregulated in the sensitized D2 receptor (Self & Nestler, 1998).  
When accelerated and unmediated, this chain reaction can happen very quickly and with 
increased frequency.  As a result, it can be assumed that the firing frequency of dopaminergic 
neurons increases as a result of D2 receptor supersensitivity (Kostrzewa et al., 2004), which 
presumably would be further accelerated when amphetamine, a potent dopamine agonist, is 
acting at the synapse and increase D2 receptor activity.  
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   In the present study, D2 primed animals exhibited a three-fold increase in accumbal 
dopamine release over nonprimed animals when both are administered amphetamine.  This 
increase in dopaminergic activity was presumably manifested in behavioral activation produced 
by amphetamine in D2-primed animals. The behavioral effects of amphetamine are thought to 
arise due to the drugs ability to increase concentrations of synaptic dopamine.  The reasons for 
this effect are four-fold.  First, amphetamine stimulates direct dopamine release from the nerve 
terminal by upregulating the dopamine transporter that is responsible for exporting dopamine 
from the cell  (Izenwasser & Cox, 1990).  Second, amphetamine produces a subsensitization of 
the D2 autoreceptor, meaning the autoreceptor, which is responsible for attenuating dopamine 
release at the nerve terminal when synaptic concentrations reach high levels, becomes much less 
responsive (Henry, Greene, & White, 1989).  Third, amphetamine blocks reuptake of dopamine 
while it also, fourth, inhibits the action of monoamine-oxidase, the enzyme responsible for 
breaking down dopamine in the synapse (Butcher, Fairbrother, Kelly, & Arbuthnott, 1990).  
When this effect is combined with a supersensitive response from D2 receptors, then the overall 
dopaminergic response is increased (Nowak et al., 2001). Nowak et al. showed a robust increase 
of dopamine in the striatum in D2-primed rats after acute amphetamine treatment, and congruent 
with this finding, the present results report a robust increase of dopamine in nucleus accumbens 
core, a brain area located directly ventral to the striatum. .    
Additionally, to help verify this hypothesis, future studies are aimed to blocking both the 
D1 and D2 receptors to analyze their specific roles in both locomotor sensitization and dopamine 
release in D2-primed rats. Past studies have shown that the D1 receptor seems to play more of a 
role in inducing the behavioral effects of sensitization (Vezina, 1996), whereas the D2 receptor 
seems to be more involved in the behavioral expression resulting from the induction of 
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 locomotor sensitization incurred from the D1 receptor (Chiang et al., 2003; Feldpausch et al., 
1998).  Changes in the sensitivity of the D1 receptor may bring about deregulation of dopamine 
release presynaptically (Kalivas & Stewart, 1991) while the effect of D2 receptor 
supersensitivity seems to effect dopamine transmission cell both pre- and post synaptically 
(Feldpausch et al., ; Nowak et al., 2001).  Thus, if the D2 receptors are supersensitized with 
neonatal quinpirole robust behavioral augmentation and dopamine release occurs. This may 
suggest that the firing rate of  dopamine neurons in this area may be further accelerated 
following chronic administration of amphetamine than it would be under normal circumstances, 
and future studies could analyze this through electrical recording in this region. .  
One concern brought to light in these data has to do with reconciling these results with 
those of Nowak et al. (2001).  In this past work, Nowak et al. demonstrated a 4-fold increase in 
dopamine release in D2-primed rats in response to an acute dose of d-amphetamine; however, 
this change in dopamine release was shown in the dorsal striatum. The dorsal striatum is a 
structure directly dorsal to the nucleus accumbens and plays a primary role in skilled motor 
movements but also communicates with the nucleus accumbens and has been shown to be 
involved in mediating some of the reinforcing actions of drugs (Belin & Everitt, 2008).  In the 
current study, it was hypothesized that because microdialysis was performed in the nucleus 
accumbens, a primary brain structure concerned with positive reinforcement, we would expect a 
much larger differential increase in dopamine in D2-primed as compared to non D2-primed rats. 
There have been several studies approaching this issue, and the results  have been contradictory. 
Whereas  (Kuczenski & Segal, 1992; Robinson & Camp, 1990) have reported no significant 
differences in dopamine release in response to ampheatmine in the dorsal striatum as compared 
to the nucleus accumbens, DiChiara and colleagues (1993, 2004) have found that amphetamine 
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 induced a larger increase in dopamine release in the core of the nucleus accumbens as compared 
to the dorsal striatum (Di Chiara et al., 2004). One of the underlying issues that has been 
suggested has to do with the placement of the microdialysis probe, and it appears that there are 
more robust increases in dopamine release in the lateral as compared to the medial striatum, and 
the lateral striatum has more anatomical similarity to the nucleus accumbens (Di Chiara, Acquas, 
Tanda, & Cadoni, 1993).  Regardless, this is an important issue, as the nucleus accubmens has 
long been hypothesized to be the brain region central to the hedonic effects of drugs.  
   A second issue with reconciling data with Nowak et al. (2001) was that this past study 
reported a 5-fold increase of dopamine release in the striatum, whereas the highest increase in 
dopamine release in the current study was a 3-fold increase in the nucleus accumbens.  However, 
it is important to consider the overall percent increase above baseline in conjunction with the 
difference between treatment groups.  In the experiment by Nowak et al., a 1050% increase in 
dopamine was observed in the striatum 40 minutes after a 1.0 mg/kg acute dose of d-
amphetamine.  In this experiment, 40 minutes following a cumulative 0.6 mg/kg dose of 
amphetamine, we observed a 1300% increase of dopamine release in D2 primed animals.  Also, 
non-D2primed animals in this experiment demonstrated a 450% increase in dopamine release as 
compared to the 250% increase observed by Nowak.  So, even at a lower dose of amphetamine, 
animals in the present study demonstrated a significantly higher overall level of dopamine 
release.  Additionally, we notice that dopamine levels actually even before the cumulative dose 
of amphetamine reaches 2.5 mg/kg, the highest dose employed in this study.  It is possible that, 
with decreased variability, dopamine levels may have even significantly decreased before the 
highest dose was administered.  This could be indicative of a ceiling effect of dopamine release, 
as dopamine stores may have been depleted, which may help to explain why a higher differential 
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 release was not seen as expected. It must also be noted that these increased levels of dopamine 
are observed 7 days following withdrawal of the drug.  It is expected that this increased 
dopamine would lead to increased euphoria and, possibly, greater reinforcement if relapse 
occurs.  Attempting to block such a substantial rebound in dopamine levels may be a possible 
future target for relapse prevention.               
Sex Differences in Amphetamine Sensitization and Accumbal Dopamine Release  
 Behavioral measures horizontal activity.  The hypothesis that females would exhibit 
greater horizontal activity than males  in response to d-amphetamine treatment was not supported 
in the present study,   Actually, D2 primed males demonstrated a significant increased horizontal 
activity response to amphetamine than all other groups.  Additionally, males show a significant 
overall increase in horizontal activity relative to females on day 6.  This finding suggests that 
dopamine activation among males in this study may actually be higher than that of females, or 
that females are demonstrating a significant increase in stereotypic behavior that would actually 
decrease their horizontal activity. Previous studies have reported that females rats are much more 
sensitive to the effects of amphetamine, both chemically and behaviorally (Becker & Cha, 1989; 
Becker et al., 1982; Kalivas & Stewart, 1991; Robinson et al., 1980). One possible explanation 
may be that males have been reported to be more sensitive to behavioral activation of the D2 
receptor (Schindler & Carmona, 2001), which could explain the significant increase in activity 
for D2 primed males. 
 However, the only time point at which males increase in horizontal activity compared to 
females is on day 6 of testing.  Taking a look at the overall patterns witnessed in these animals, it 
appears that activity in amphetamine-treated females appears to be fluctuating while activity in 
amphetamine treated males shows a more continuous increased locomotor response to 
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 amphetamine, which is a more typical  pattern of locomotor sensitization to psychostimulants.  
Horizontal activity in females appears to asymptote on day 5 and decrease on day 6.  However, 
amphetamine-treated males maintain their highest levels of activity on day 6.  Previous research 
suggests that dopamine levels may decrease, as dopamine stores become exhausted following 
prolonged stimulant exposure (Koob et al., 2004).  So, it may be that case that if females are 
indeed more reactive to the effects of psychostimulants, they may be experiencing this decrease 
sooner that the males, who do not exhibit any signs of a decrease.  This may explain the inverse 
of the expected seen effect on this day. Alternatively, females may be demonstrating a significant 
increase in stereotypic behaviors such as grooming, paw treading, and vacuous chewing 
movements, which would actually decrease horizontal activity but may be a manifestation of 
increased dopmainergic activity.  
 Path stereotypy. No significant sex differences were observed on the path stereotypy 
measure. This finding is contrary to   previous research that has suggested females demonstrate 
increased stereotypy in response to amphetamine; however, it depends on the behaviors that are 
measured (Becker et al., 2001). On the other hand, there is research to suggest that Sprague-
Dawley rats may be much more responsive to stimulants in terms of both horizontal activity and 
stereotypy (Horowitz, Kristal, & Torres, 1997).  If it is the case that our animals are reaching an 
apex in behavioral responding to amphetamine, the use of Sprague-Dawley rats may be further 
contributing to obscuring of sex differences in this instance.  Further study might seek to 
investigate these measures in other species where behavioral responding may not be as robust so 
to allow identification of a differential in responding resulting from sex. 
 Immobility time.  The hypothesis that females would spend a significant increase in  time 
in immobility than males was not supported.  It was hypothesized that if females were exhibiting 
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 higher levels of stereotypy, it would result in greater levels of immobility because behaviors such 
as chewing, grooming, and paw treading are not quantifiable using AnyMaze.  However, while 
these behaviors are occurring, the animals are not recording activity counts as previously 
discussed, so the animal is considered to be immobile. Males administered amphetamine actually 
exhibited greater time in immobility compared to females on days 1 and 2, which suggests a  
higher initial locomotor activation to amphetamine in females. This result supports the claim that 
females may be more activated by amphetamine after acute administration. Although this has not 
been shown in past work, it suggests that females may be more behaviorally activated by initial 
amphetamine treatment.   
 Dopamine microdialysis.  Although D2 primed females exhibited a 41% increase in 
dopamine release compared to D2 primed males when both are administered amphetamine, no 
significant sex differences were observed in these data.  This is likely due to the high variability 
observed in the D2 primed females.  It is important to note, however, that this variability is not 
observed in the other treatment groups. We hypothesize that one reason this may be the case is 
that the level of priming of the D2 receptor may be different across subjects.  This observation is 
supported in the literature through the yawning test. Past studies from our lab have reported some 
variability in yawning of D2-primed subjects, ranging from as low as 8-22 yawns in an hour in 
males, and approximately 3-7 yawns in an hour in females (Brown et al., 2002, 2004; Maple et 
al., 2007). These result suggests some variability in the sensitivity in the dopamine D2 receptor 
across subjects and across studies (Cooper et al., 1989; Kostrzewa et al., 1995). This being the 
case, it is uncertain whether increasing the number of subjects will enhance statistical power 
sufficiently to observe a significant sex difference in these data. Nonetheless, this supports the 
claim that there is extensive dysfunction in D2 primed females administered amphetamine, 
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 which may help to explain why schizophrenic females seem to be differentially affected by 
psychostimulants in comparison to schizophrenic males (Gearon & Bellack, 2000). It is also 
suggests that our model may represent both mild and severe forms of schizophrenia, at least 
based on sensitivity of the D2 receptor.  
Conclusion 
 It appears neonatal treatment with quinpirole resulting in supersensitivity of the D2 
receptor produced increased behavioral and neurochemical measures when animals were 
chronically exposed to amphetamine.  This suggests these animals may be differentially 
vulnerable to psychostimulant addiction.  Additionally, assuming D2 supersensitivity is a 
potential model of the dopamine dysfunction witnessed in schizophrenia, this interaction of D2 
neonatal drug treatment increasing the effects of adulthood drug treatment may shed light on the 
schizophrenics’ propensity to abuse psychostimulant drugs.   
 It is uncertain if sex differences play as prominent of a role in this interaction.  Females 
may indeed be differentially responsive but further experimentation is required. It appears that 
females may be more acutely affected by amphetamine than males as evidenced by decreases in 
immobility on the initial day of treatment.  Additionally, horizonal activity  in females appears to 
reach peak levels more quickly than is seen in males.  This would suggest that dopamine release 
in females may be more robust initially than in males.  However, as a result, dopamine may 
become more quickly depleted in females.  Nonetheless, the high levels of variability in female 
D2 primed animals given amphetamine indicates substantial dysregulation of dopamine in these 
animals.  
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      schizophrenia” 
      2nd Place Award 
      Winner Student's Choice Award 
 
      2008 ETSU Student Research Forum Graduate  
      Student Presentation 
      “D-amphetamine sensitization and microdialysis in  
      a rodent model of psychosis” 
      2nd Place Award 
 
Extracurricular Activities:   Graduate and Professional Student Association 
      Active Member 
 
      Graduate Student Association in Psychology 
      Active Member 
 
      Society for Neuroscience 
      Student Member 
 
      Appalachian Chapter for the Society for   
      Neuroscience 
      Student Member  
 
      ETSU Catholic Campus Ministries 
      Active Member 
      Student Council President, Academic Year 2001- 
     2002 
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